MedTrace Logo

Stem Cell Treatment for Lung Injury Caused by Major Infectious Diseases

NCT06416709 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2024-05-16

No results posted yet for this study

Summary

The goal of this study is to conduct a prospective, double-blind, randomized placebo-controlled clinical trial to investigate the safety and efficacy of mesenchymal stem cells treatment for Lung injury caused by major infectious diseases.

Conditions

  • Lung Injury

Interventions

DRUG

mesenchymal stem cells

Mesenchymal stem cell dose is 5×10\*7/10ml and is transplanted by intravenous infusion. The cells are used once every three days and for three times

OTHER

saline

10 ml saline is used as placebo once every three days and for three times

Sponsors & Collaborators

  • Beijing 302 Hospital

    collaborator OTHER

  • Cell Energy Life Sciences Group Co. LTD

    lead INDUSTRY

Principal Investigators

  • Fu sheng Wang, Dr · Beijing 302 Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-10
Primary Completion
2026-05-10
Completion
2026-05-10

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06416709 on ClinicalTrials.gov